Pfizer Corporation

Bristol-myers Squibb Compnay

E. R. Squibb Sons, Inc.

Medarex Inc.

Tim Sproul

Mark Yamanaka

Kristopher Toy

Dawn M Tanamachi

Haichun Huang

Heidi N Leblanc

David J King

Brigitte Devaux

Peter Brams

Alison Witte

Steven Lee Bender

David B Passmore

Haibin Chen

Richard Theolis

Chetana Rao-Naik

Kyra D Zens

Lan Yang

Michael Aidan North

Gerald Fries Casperson

Dana Dan Hu-Lowe

Xin Jiang

Gang Li

Jianying Wang

Asna Masood

Sarah R Reed

Grant Wickman

Jonathan Alexander Terrett

Chin Pan

Li-Sheng Lu

Dapeng Yao

Sara R Dwiggins

David John King

The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

Human antibodies that bind CD22 and uses thereof

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.

Monoclonal antibodies against Glypican-3

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin &#x3b1;5&#x3b2;1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-&#x3b1;5&#x3b2;1 antibodies or antigen binding portions thereof described herein.

Alpha5-beta1 antibodies and their uses

Alpha 5-beta 1 antibodies and their uses

Growing community of inventors

Livermore, CA, United States of America

Tim Sproul